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Abstract
Purpose Optimal ciclosporin A (CsA) exposure in kidney
transplant recipients is difficult to attain because of variabil-
ity in CsA pharmacokinetics. A better understanding of the
variability in CsA exposure could be a good means of
individualizing therapy. Specifically, genetic variability in
genes involved in CsA metabolism could explain exposure
differences. Therefore, this study is aimed at identifying a
relationship between genetic polymorphisms and the vari-
ability in CsA exposure, while accounting for non-genetic
sources of variability.
Methods De novo kidney transplant patients (n=33) were
treated with CsA for 1 year and extensive blood sampling
was performed on multiple occasions throughout the year.
The effects of the non-genetic covariates hematocrit, serum
albumin concentration, cholesterol, demographics (i.e.,
body weight), CsA dose interval, prednisolone dose and
genetic polymorphisms in genes encoding ABCB1,
CYP3A4, CYP3A5, and PXR on CsA pharmacokinetics
were studied using non-linear mixed effect modeling.
Results The pharmacokinetics of CsA were described by a
two-compartment disposition model with delayed absorption.
Body weight was identified as the most important covariate
and explained 35% of the random inter-individual variability
in CsA clearance. Moreover, concurrent prednisolone use at a
dosage of 20 mg/day or higher was associated with a 22%
higher clearance of CsA, hence lower CsA exposure. In
contrast, no considerable genotype effects (i.e., greater than
30–50%)on CsA clearance were found for the selectedgenes.
Conclusions It appears that the selected genetic markers
explain variability in CsA exposure insufficiently to be of
clinical relevance. Therefore, therapeutic drug monitoring is
still required to optimize CsA exposure after administration
of individualized doses based on body weight and, as this
study suggests, co-administration of prednisolone.
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Introduction
The trend toward lowering the exposure of the calcineurin
inhibitor ciclosporin (CsA) is widely propagated [1] as CsA
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the clinical endpoints rejection and toxicity [2]. Since
therapy with CsA is characterized by considerable inter-
and intra-individual variability [3] in its pharmacokinetics
(PK), it is difficult to remain within the therapeutic window.
Therefore, to optimize therapy in clinical practice, thera-
peutic drug monitoring (TDM), aimed at individualized
CsA dosing is common practice [2, 4, 5]. As a next step, to
further optimize CsA therapy, insight into the sources of
this variability in CsA exposure is necessary.
It has been demonstrated that the observed variability in
CsA PK originates from non-genetic biological and
lifestyle-related factors, including age, body size, gender,
food intake [3], serum albumin concentration, hematocrit,
lipoproteins (HDL, LDL) [6, 7], and co-administration of
interacting drugs [3, 8–11]. Yet, even when these factors are
taken into account, a considerable part of the variability
remains unexplained, which could potentially be attributed to
genetic differences between patients. Insight into this
relationship could aid in optimizing CsA exposure early
after transplantation. Indeed, CsA disposition is characterized
by extensive metabolism by cytochrome P450 (CYP)
enzymes [12, 13]. Moreover, CsA is a substrate for the
efflux pump P-glycoprotein (ABCB1) [12, 13]. Recently, the
pregnane X receptor (PXR) was reported to be the key
nuclear receptor regulating expression of cytochrome
enzymes and certain transport proteins and mediating their
induction [14–16]. To date, no studies have been published
relating CsA PK parameters to polymorphisms in PXR.
Several investigators have studied the role of genetic variants
in genes encoding for the drug metabolizing enzymes
CYP3A4, CYP3A5, and the multidrug resistance transporter
ABCB1 [13, 17]. These studies show conflicting results with
regard to the contribution of single nucleotide polymor-
phisms (SNPs) in ABCB1 C1236T, T3435C, G2677A and T-
129C, CYP3A4*1B, and CYP3A5*1 [18–22].
A limitation of many studies is that often other sources
of variability, which can mask the actual relationship
between genetic factors and CsA exposure, have not been
taken into account. This is especially the case because
associations between SNPs in these enzymes are mainly
related to dose-corrected trough concentrations, which are
not a very sensitive measure of variability in exposure. An
integrated analysis on the basis of full concentration vs time
profiles, accounting for the observed variability in CsA PK
by including a wide range of covariates, is the approach for
identifying any relationship between CsA exposure and
genetic polymorphisms in genes encoding CYP3A4,
CYP3A5, P-glycoprotein or the pregnane X receptor.
Therefore, in this study, a population analysis of CsA PK
was performed, aimed at a comprehensive exploration of
the determinants for individualizing the CsA dose in kidney
transplant recipients.
Materials and methods
Patients and therapy
De novo kidney transplant patients (n=33) aged between
18 and 70 years were followed for 1 year after transplan-
tation (Table 1). Recipient, donor, and transplant character-
istics as well as outcome parameters (acute rejection rate,
patient and graft survival, and renal function) are summa-
rized in Table 1. Only recipients of a first kidney graft from
a deceased or living (non-HLA-identical) donor were
included. From each patient written informed consent was
obtained. The study was performed in accordance with the
Declaration of Helsinki and was approved by the Medical
Ethics Committee of the Leiden University Medical Center.
Patients received quadruple immunosuppression consist-
ing of induction therapy with basiliximab on the day of
transplantation and on day 4, a fixed dose (1,000 mg twice
daily) of mycophenolate mofetil (MMF), prednisolone
(50 mg twice daily on the day of transplantation, but rapidly
tapered toward 10 mg once daily at day 22) and CsA
(Neoral®). Patients were randomized to receive a CsA daily
dose of 8 mg/kg/day in either a once or twice daily regimen
(Table 1). TDM for twice daily CsA was aimed at a target
AUC of 5,400 µg*h/L in the first 6 weeks and at
3,250 µg*h/L after this period. Likewise, for the once daily
regimen these values were 10,800 µg*h/L and 6,500 µg*h/L
respectively.
Therapeutic drug monitoring
Therapeutic drug monitoring (TDM) was performed on the
basis of a limited sampling strategy (blood concentration at
t=0, 2, and 3 h) and the Bayesian estimation of the AUC[0–
12 h] using MW/Pharm version 3.5 (Mediware, Groningen,
The Netherlands), as described previously [4]. Routine
TDM samples were taken during the mornings of weeks 4,
8, 10, 17, 21, and 39 after transplantation. In addition, PK
was densely sampled in weeks 2, 6, 12, 26, and 52 with
samples at t=0, 1, 2, 3, 4, 6, and 24 h. A majority of
patients (22) was sampled on each of the eleven study
occasions, while 6 patients were sampled on ten occasions
and 2 patients on twelve occasions. The remaining 3
patients were sampled less frequently (ranging from three
to six occasions). Furthermore, at every TDM visit CsA
dosage information was recorded, which consisted of the
actual time of dosing (that morning) and the time of dosing
the evening before, as well as the amount and dose interval.
As patients had to use the same dose for at least 3 days to
reach a steady state, the start of therapy or the last date of
dose change was recorded.
Ciclosporin A concentrations were determined in
whole blood by fluorescence polarization immunoassay
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and analyzed according to the manufacturers’ instruc-
tions. Assay inter-day variation derived from routine
measurements was: 10.4% (70 µg/L, low level), 7.8%
(300 µg/L, medium level), and 7.5% (600 µg/L, high
level). The assay was linear up to a concentration of
800 µg/L.
Genotyping assays
The DNAwas isolatedfromEDTA blood.Primersand probes
used in the Taqman-based genotyping assays, as well as
primers and sequences used in the pyrosequence assays are
listed in Table 2. ABCB1 C1236T (rs1128503), T3435C
(rs1045642), and G2677T (rs2032582) were determined with
Variable Once daily Twice daily p value
(N=17) (N=16)
Recipient characteristics
Age (mean ± SD) 43.8±14.5 48.9±10.5 0.79
Male sex (n) 15 11 0.23
Caucasian (n) 14 12 0.69
Native kidney disease 0.29
Pyelonephritis 0 2
Glomerulonephritis 6 6
Hereditary/congenital 2 4
Hypertension 4 0
DM 1 2
Other 2 1
Unknown 2 1
Donor characteristics
Age (mean ± SD) 44.9±16.7 43.1±12.6 0.72
Male sex (n) 7 6 0.83
DD heart beating 7 9 0.49
DD non-heart beating 6 1 0.09
LRD 2 4 0.40
LURD 2 2 0.95
Transplant characteristics
HLA mismatch mean ± SD 2.00±1.50 2.38±1.82
Class I 1.47±1.23 1.63±1.36 0.79
Class II 0.53±0.51 0.75±0.68 0.40
Cold ischemia time (h) DD only 19.9±4.3 23.0±8.4 0.25
Acute rejection 6 months (n) 4 2 0.40
Need for ATG (n) 3 1 0.33
Patient survival (n)
1 year 17 16
2 years 17 16
Death-censored graft survival (n) 0.60
1 year 16 16
2 years 16 16
Nankivell clearance (mean ± SD) 0.44
Week 2 45±23 48±21
Week 6 62±17 61±15
Month 3 64±14 61±13
Month 6 68±16 64±10
Month 9 68±15 63±11
Year 1 69±17 64±12
Year 2 64±16 60±11
Table 1 Clinical characteristics
DM diabetes mellitus, DD de-
ceased donor, LRD living related
donor, LURD living unrelated
donor, HLA human leukocyte
antigen, ATG anti-thymocyte
globulin, SD standard deviation
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SNP Target Sequence 5′-3 Modification
a
ABCB1 C1236T PCR-f CACCGTCTGCCCACTCT
PCR-r GTGTCTGTGAATTGCCTTGAAGTTT
Probe-T TTCAGGTTCAGACCCTT VIC
Probe-C CAGGTTCAGGCCCTT FAM
ABCB1 G2677T PCR-f CTTAGAGCATAGTAAGCAGTAGGGAGT
PCR-r GAAATGAAAATGTTGTCTGGACAAGCA
Probe-G TTCCCAGCACCTTC VIC
Probe-T TTCCCAGAACCTTC FAM
ABCB1 T3435C PCR-f ATGTATGTTGGCCTCCTTTGCT
PCR-r GCCGGGTGGTGTCACA
Probe-T CCCTCACAATCTCT VIC
Probe-C CCCTCACGATCTCT FAM
Pyrosequence
ABCB1 T-129C PCR-f TCGAAGTTTTTATCCCA Biotine
PCR-r CCTCCTGGAAATTCAACCTGTT
Sequence primer TACTCCGACTTTAGTGGAAAGACC
Target sequence CTG/ACTCGAATGAG
CYP3A5*3 PCR-f CTGCCTTCAATTTTTCACT
PCR-r TATGTTATGTAATCCATACCCC Biotine
Sequence primer AGAGCTCTTTTGTCTTTCA
Target sequence A/GTATCTC
CYP3A4*1B PCR-f CAGCCATAGAGACAAGGGC
PCR-r GAAGAGGCTTCTCCACCTT Biotine
Sequence primer CCATAGAGACAAGGGCA
Target sequence A/GGAGAGAGG
CYP3A5*6 PCR-f TCTTTGGGGCCTACAGCATG
PCR-r AAAGAAATAATAGCCCACATACTTATTGAGAG Biotine
Sequence primer AGAAACCAAATTTTAGGAA
Target sequence CTTC/TTTAG
PXR C-25385T PCR-f GTGGTCATTTTTTGGCAATCCC
PCR-r AGCCTCTGGCAACAGTAAAGCA Biotine
Sequence primer TTGGCAATCCCAGGT
Target sequence TC/TTCTTTTCTACCTGTT
PXR A-24381C PCR-f AGTGGGAATCTCGGCCTCA
PCR-r CTGGGGTCCACTTTGAACAATC Biotine
Sequence primer GCTAATACTCCTGTCCTGAA
Target sequence A/CAAGGCAGCGGCTCCTTG
PXR G-24113A PCR-f GAATCATGTTGGCCTTGCTGC
PCR-r GCATCAGTAATGGGGCTCAAC Biotine
Sequence primer TCTCCTCATTTCTAGGGT
Target sequence C/TCACCCTAG
PXR A+252G PCR-f TGCAAGGGCTTTTTCAGGTAGAGT
PCR-r TGAACCTGGGGGATAGGTCAAG Biotine
Sequence primer ACTGACCCACTGGGTAA
Target sequence CA/GTCTCAGGGC
PXR A+7635G PCR-f AGCCATCCTCCCTCTTC Biotine
PCR-r CAGCAGCCATCCCATAATC
Sequence primer CATAATCCAGAAGTTGGG
Target sequence GGC/TGAGAGGAA
f forwardorientated, r reverse orientated, ABC ATP-binding cassette, CYP cytochrome P450, PXR pregnane X receptor, PCR polymerase chain reaction
aVIC and FAM are fluorescent dyes, biotine is necessary to obtain single-stranded DNA
582 Eur J Clin Pharmacol (2010) 66:579–590TaqMan 7500 (Applied Biosystems, Nieuwerkerk aan den
IJssel, The Netherlands) with custom designed assays,
according to the manufacturer’sp r o t o c o l .ABCB1 T-129C
(rs3213619), CYP3A5*3/*6 (rs776746/rs10264272),
CYP3A4*1B (rs2740574), and NR1I2 or PXR SNPs C-
25385T (rs3814055), A-24381C (rs1523127), G-24113A
(rs2276706), A+252G (rs1464603), and A+7635G
(rs6785049) [14, 15] were determined with Pyrosequencer
96MA (Isogen, IJsselstein, The Netherlands). In short, PCR
reactions contained 10 ng of DNA, and 5 pmol of each PCR
primer (Table 2) in a total volume of 12 μL. Cycle
conditions were: initial denaturation for 15 min at 95°C, 35
cycles of 95°C–55°C–72°C each for 30 s, ending with
10 min at 72°C. The pyrosequence reactions were performed
according to the manufacturer’sp r o t o c o l .T h es e q u e n c eu s e d
for analysis and the calculated dispensation order for each
SNP are listed in Table 2. Note that the lower case
nucleotides in the dispensation sequence are negative
controls, which are not incorporated into the target DNA
and consequently should not appear in the pyrogram. As
quality control, 5% of samples were genotyped in
duplicate. In addition, negative controls (water) were
used. The allele frequencies were found to be in Hardy–
Weinberg equilibrium. Table 3 presents the genotype
distribution in the overall genotyped population. The
haplotype analysis for ABCB1 SNPs that are in linkage
disequilibrium was performed using gPLINK with hap-
lotypes set with a certainty greater than 0.97.
Population pharmacokinetic analysis
The PK of CsA was analyzed by non-linear mixed effects
modeling. Mixed effects models consist of a structural
model, describing the relationship between dose and
concentration in terms of structural PK parameters (i.e.,
CL, V), and a stochastic model, describing the random
variability in the structural model parameters. The random
effects are the expression of inter-individual and inter-
occasion variability. Inter-individual variability describes
the random variability of structural parameters within the
population, whereas inter-occasion variability describes the
variability of an individual parameter value from one
occasion to another. The second level of stochastic effects,
σ
2, describes the variability of the difference between
observed and predicted responses. This residual error
includes, among other factors, model mis-specification,
intra-individual variability, and measurement error. In the
mixed effects modeling approach, structural and stochastic
parameters are simultaneously estimated by fitting the
model to the data. In this respect the following parameters
were estimated: PK parameters, variance and covariance
(ω
2) of each individual specific parameter value (η) and
variance (σ
2) of the residual error. As a result, individual
post hoc estimates of parameters associated with inter-
individual and inter-occasion variability could be obtained.
Structural model
The PK of CsA was fitted to linear compartmental models.
The value for the oral bioavailability was fixed at 50%, as
previously described [3, 23] and used in the clinically
applied TDM model [4].
Random effects
Inter-individual variability (IIV) and inter-occasion vari-
ability (IOV) were described assuming a log normal
distribution with the following equation:
Table 3 Genotype distribution in the study population (n=33). The number of individuals carrying a certain genotype are presented
SNP Frequency
ABCB1 T3435C T/T 9 C/T 12 C/C 10 2 UG
ABCB1 G2677T G/G 10 G/T 13 T/T 7 3 UG
ABCB1 C1236T C/C 10 C/T 14 T/T 7 2 UG
ABCB1 T-129C T/T 29 C/T 2 C/C 0 2 UG
CYP3A4*1B A/A 27 G/A 3 G/G 1 2 UG
CYP3A5*3 G/G 25 A/G 4 A/A 2 2 UG
CYP3A5*6 C/C 28 C/T 3 T/T 0 2 UG
PXR C-25385 T C/C 7 C/T 16 T/T 8 2 UG
PXR A-24381C A/A 6 A/C 15 C/C 10 2 UG
PXR G-24113A A/A 8 G/A 16 G/G 7 2 UG
PXR A+252G A/A 10 G/A 15 G/G 6 2 UG
PXR A+7635G A/A 6 G/A 19 G/G 6 2 UG
Frequency determined in successfully genotyped individuals
SNP single nucleotide polymorphism, ABC ATP-binding cassette, CYP cytochrome P450, PXR pregnane X receptor; UG unsuccessfully
genotyped (2 individuals in particular)
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in the jth individual and ηjPK is the difference between the
individual specific parameter and the population value.
TVPK is the population value of the PK parameter and the
difference in the logarithm between the individual value of
the subject j and the population mean (ηjPK) is normally
distributed with a mean of zero and variance ωPK
2. The
residual error was assumed to be additive to the predicted
concentration after log transformation: log Cij ðÞ ¼
log Cpredij ðÞ þ "ij in which cij is the Ith observation for
the jth individual, Cpredij is the concentration of CsA in the
blood predicted by the PK model, and εij (the difference
between Cij and Cpredij) is a normally distributed variable
with a mean of zero and variance σ
2.
Covariate analysis
The non-genetic biological and life-style covariates hemat-
ocrit, serum albumin concentration, prednisolone daily
dose, CsA dose regimen, cholesterol (LDL, HDL), the
demographic factors body weight, age, sex, and body
surface area (BSA), and the genetic markers for ABCB1
(T3435C, G2677T, C1236T, T-129C), CYP3A4 (*1B),
CYP3A5 (*3,*6), and NR1I2/PXR (C-25385T, A-24381C,
G-24113A, A+252G, A+7635G) were selected on the basis
of their known or theoretical relationships with CsA PK.
Covariates with a clear visual relationship between the
random effects in the model without covariates (base
model) and the covariate values were formally tested with
the model. When the relationship was described allometri-
cally (i.e., in a body weight-adjusted manner), it was done
in the form PK = TVPK x (BW /meanBW)
y, where BW is the
individual body weight value, meanBW is the body weight
population mean, and y is the allometric exponent, typically
with a value of 0.75 for clearance and 1 for volume of
distribution [24]. Subsequently, the selected covariate
relationships were evaluated by a forward inclusion and a
backward deletion procedure [25]. Including a covariate
effect should result in a reduction in the identified random
variability and an improvement in the model fit.
Computation
Non-linear mixed effects modeling (NONMEM, version VI
release 1.2, Icon Development Solutions, Ellicott City, MD,
USA) [26] was used for modeling CsA PK. Modeling
results were analyzed using the statistical software package
S-Plus® for Windows (version 6.2 Professional; Insightful,
Seattle, WA, USA). A convergence criterion of 3 significant
digits in the parameter estimates was used. For model
comparisons, the minimum value obtained of the objective
function (MVOF), defined as minus twice the log likeli-
hood, was used. First-order conditional estimation (FOCE)
with interaction was used throughout the modeling process.
The modeling process was guided by statistical and visual
checks (i.e., diagnostic “goodness of fit” plots). A model
parameter or a covariate was retained in the model when
including this parameter in the model resulted in a decrease
of 6.63 points (χ
2 distribution, 1 degree of freedom, p=
0.01) in the minimum value of the objective function
(ΔMVOF≥6.63) or vice versa with backward deletion from
the model. This conservative p value (Type I error) was
selected, since it is known that the NONMEM FOCE
method produces only an approximation to the maximum
likelihood assumptions and that the null hypothesis will be
rejected more frequently than the nominal Type I error
value [27].
Visual predictive check
The model prediction was evaluated using a visual
predictive check (VPC), which evaluates whether the
identified model would be able to predict the observed
variability for 80% of the population in the PK data that
were used for model identification [28]. Therefore, the PK
of each individual using its individual specific dosing
history and covariate values was simulated using the
individual specific values for dose and covariates. In a
Monte Carlo simulation, 100 datasets were simulated by
drawing random samples for the PK parameters from the
identified distributions for inter-individual variability, inter-
occasion variability, and residual variability. The distribu-
tion (median and 10th and 90th percentiles) of the
simulated concentration–time courses was compared with
the distribution of the observed values in the original
dataset. Differences and overlap of the simulated and
original distributions indicate the accuracy of the identified
model.
Bootstrap
A bootstrap analysis was performed to assess the precision
of the PK parameter estimates. The observed dataset was
re-sampled with replacement in order to generate a new
dataset with the same size and population characteristics,
such as the number of patients per genotype, as the original
set. This procedure was repeated 500 times to generate a
distribution of the PK parameters with a mean and
coefficient of variation as well as the median and 2.5th
and 97.5th percentiles.
Results
Ciclosporin A PK is characterized by variable peak
concentrations in the first 3 h after administration. The
584 Eur J Clin Pharmacol (2010) 66:579–590variability in the delayed absorption of CsA could best be
described with a transit compartment, using a first-order
rate constant describing the transfer from the dose com-
partment into the transit compartment and subsequently into
the central compartment (Fig. 1). Distribution and elimina-
tion of CsA could be adequately described by a two-
compartment model with first-order elimination (Fig. 1).
Random effects for the inter-individual variability were
estimated for clearance; the volume of the central compart-
ment and the absorption rate were constant.
The value of the absorption rate constant varied from 0.5
to 3.2 h
−1. The first-order transit rate constant is set to be
equal to the absorption rate constant; thus, the transit time
can be calculated with 1/ka*(n+1), where n is the number
of transit compartments [29]. The transit time or lag time
was typically 1 h (range 0.6 to 4 h). A concomitant
prednisolone dose of 20 mg/day or higher was related to a
55% lower CsA absorption rate (ΔMVOF=+233 points,
deletion from the final model, Table 4).
The range in apparent clearance (CL/F) in the population
was 13–64 L/h, with a median of 32 L/h. The relationships
among body weight, CsA clearance, and the central volume
of distribution were described allometrically and the
parameters were scaled to the median body weight, i.e.,
CL=15 × (body weight/76)
0.75. The body weight range in
the population was 49 to 140 kg with a median of 76 kg.
Incorporating body weight into the model explained 9% of
the inter-individual variability in CL/F (decrease from 26 to
17%, while it accounted for 8% (decrease from 43 to 35%)
of the inter-individual variability in the volume of the
central compartment (ΔMVOF=+17 when deleting the
effect of body weight on both parameters from the final
model). This means that, relative to the observed variability,
35% and 19% of the inter-individual variability in these
parameters are explained by the covariate body weight
respectively.
Inter-occasion variability was estimated for the fixed
bioavailability term (Table 4) and not for the clearance term
because of a better model fit. The model clearly improved
when accounting for a 22% lower bioavailability if a
prednisolone dose of 20 mg/day or higher was co-
administered (ΔMVOF=+51, deletion from final model).
This accounted for 20% of the inter-occasion variability as
the variability value decreased to 14%.
The model including CL/F and V/F scaled to individual
body weight and the effect of concomitant prednisolone
administration adequately described the CsA concentrations
in time as shown by the results of the Visual Predictive
Check (Fig. 2), which displays the observed and predicted
variability in the concentration measurements. The medians
of the observed and simulated CsA concentrations are
similar (Fig. 2); the same holds for the 80% prediction
interval compared with the 10th and 90th percentiles of the
observed data. This model was therefore considered the
base model for further covariate analysis.
Besides body weight and prednisolone use in a daily
dose of 20 mg or higher, none of the selected demographic,
clinical chemistry or other non-genetic covariates displayed
a significant relationship with apparent clearance, apparent
central volume of distribution or absorption rate (ka). In
addition, none of the selected genetic polymorphisms had a
significant relationship with CL/F when tested on the base
model. Furthermore, no relationship between haplotypes for
ABCB1 genotypes and apparent clearance was found. In
Table 5 the haplotype combinations and frequencies are
presented.
Finally, the AUC monitoring strategy over time in this
population of kidney transplant patients is depicted in
Fig. 3. This illustrates the procedure of adjusting the daily
dose to a preset target in terms of AUC0–24 h.
Discussion
Explaining variability in CsA pharmacokinetics is impor-
tant to reach target exposure early after transplantation. The
current trend toward minimizing exposure to calcineurin
inhibitors [1] requires insight into the sources of variability
in CsA pharmacokinetics, because of an increased risk of
acute rejection episodes. A multitude of factors can be
responsible for the variability in the pharmacokinetics.
From the literature, an array of non-genetic biological and
lifestyle-related factors were selected, including age, body
size, gender, food intake [3], serum albumin concentration,
hematocrit and lipoproteins (HDL, LDL) [6, 7], and co-
administration of interacting drugs [3, 8–11] known to
affect CsA PK. Moreover, a number of genetic variants in
genes encoding for the involved drug-metabolizing
enzymes CYP3A4 and CYP3A5 and the multidrug resis-
CENTRAL
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transit 
compartment
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Fig. 1 Linear two-compartment model with first-order absorption and
elimination and a transit compartment in order to describe the
variability in the absorption phase
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associating single genetic variants in these genes, not
considering other non-genetic factors, have been per-
formed, but show conflicting results [22, 30]. With respect
to PXR, there are no studies published that explore the
relationship of genetic variants in this gene with CsA PK
parameters in adult renal transplant recipients.
This leads to an integrated or population analysis combin-
ing genetic and non-genetic factors. A total of seven genetic
polymorphisms in CYP3A4, CYP3A5,a n dABCB1 enzymes
Table 4 Population pharmacokinetic parameters for ciclosporin A (CsA) obtained from the bootstrap of the final model. This table shows the
mean and coefficient of variation of the pharmacokinetics (PK) parameter estimates as well as the median and percentiles of these estimates. The
variability concerns the actual random variability in the PK parameter relative to the population mean value
PK parameter Mean value Variability (%) CV (%) Median Percentiles 2.5–97.5 (%)
Absorption rate constant (ka,h
−1)
a 2.0 11 2.0 1.6 to 2.5
DDPR≥20 mg −55%
b −10 −56% −66 to 42
Number of transit compartments 1
Transit time or lag time (h)
a 1
CsA clearance (L/h) 15 4 15 14 to 16
Central volume of distribution (Vc) (L) 56 7 57 49 to 64
Peripheral volume of distribution (Vp) (L) 125 10 125 100 to 149
Intercompartmental clearance (Q) (L/h) 14 9 14 12 to 16
Bioavailability (F): 0.5
DDPR≥20 mg −22%
b −13 −22% −27 to 16
IIV absorption rate 0.09 30 31 0.09 0.04 to 0.16
IIV clearance 0.03 17 24 0.03 0.02 to 0.05
IIV central volume of distribution 0.12 35 40 0.11 0.05 to 0.24
IOV bioavailability 0.02 14 17 0.02 0.01 to 0.02
Residual variability 0.07 26 10 0.07 0.06 to 0.09
DDPR daily dose prednisolone, SE standard error, CV coefficient of variation, IOV inter-occasion variability; IIV inter-individual variability
aTransit time with one transit compartment is equal to: 1/ka*2
bThese numbers mean a 55% lower value for the absorption rate constant and a 22% lower value for CsA bioavailability
Table 4 Population pharmacokinetic parameters for ciclosporin A
(CsA) obtained from the bootstrap of the final model. This table shows
the mean and coefficient of variation of the pharmacokinetics (PK)
parameter estimates as well as the median and percentiles of these
estimates. The variability concerns the actual random variability in the
PK parameter relative to the population mean value
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Fig. 2 The visual predictive
check with the 80% prediction
interval (area between the outer
solid lines). The middle solid
line represents the median of the
model prediction. The observed
concentrations are shown as
closed symbols, whereas the
median of the observed concen-
trations per time point are
shown with the stripe (-) sym-
bol. The dotted lines indicate the
10th and 90th percentiles of the
observed data
586 Eur J Clin Pharmacol (2010) 66:579–590were included in the analysis. In addition, a relationship
between the five selected genetic polymorphisms in the
pregnane X receptor could not be related to CsA PK.
Interestingly, two covariates did appear to be relevant for
individualizing therapy, body weight, and prednisolone dose.
In our analysis body weight explained 35% of the variability
in CsA clearance between patients, while a prednisolone
dose of over 20 mg/day explained 20% of the within-patient
variability in apparent clearance. After taking the relevant
covariates into account, 17% of inter-individual variability in
clearance remained unexplained (Table 4).
Earlier studies have been inconclusive with regard to the
relationship between CsA exposure and genetic polymor-
phisms in CYP3A4 and P-glycoprotein (ABCB1/MDR1)
[18–21, 31]. In contrast to the current study, these studies
mostly used dose-adjusted trough concentrations as a
measure of drug exposure. It is known that trough
concentrations correlate poorly with exposure in terms of
AUC [4]. In our study full PK profiles were obtained,
which made it possible to accurately estimate AUC and
hence apparent clearance. In addition, the PK parameter
clearance obtained with a population model is very
sensitive to detecting a covariate effect (i.e., a genotype
effect) as one can account for the contributions of other
covariates in the analysis. The population analysis method-
ology used in the present study differentiates between
structural variability (within an individual) and random
variability (between individuals). In contrast to non-
population-based approaches this results in greater statisti-
cal power to identify a covariate effect, because two sources
of information are used instead of one. When analyzing
multiple observations per subject one is able to compensate
for the small number of individuals. Still, this study was not
designed primarily to identify genotype effects. Therefore,
we performed a posterior power calculation to estimate the
minimum genotype effect that could be identified with a
power of 80% and 95% confidence [32]. This was done for
genotypes with a frequency of 10, 20, and 30% based on
Table 3. For a genotype frequency of 10, 20 or 30% the
minimum genotype effect that could be detected with a
power of 80% was 55%, 35% or 32% respectively. This
raises the question whether the genotype effects that could
not be identified with a power of 80% (e.g., the effect of
Table 5 ABCB1 haplotype table, which contains respectively the
SNPs ABCB1 T3435C (rs1045642), C1236T (rs1128503), and
G2677T (rs2032582). This table shows the frequencies of the
haplotype combinations on the left side, while on the right side the
frequency of the individual triplets among the total amount of 60
triplets, 2 loci (of 3 alleles) ×30 individuals, is presented
Haplotype
(n=30)
Total triplets (n=60)
HAP1 HAP2 n per
group
Haplotype frequency
(%)
TTT CCG 10 CCG 0.45
CCG CCG 7 TTT 0.38
TTT TTT 6 TCG 0.10
TTT TCG 2 CTT 0.03
CTT CCG 1 CTG 0.03
CCG CTG 1 CCT 0.01
CTT TTT 1
TCG TCG 1
CCG TCG 1
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Fig. 3 The AUC0–24h vs time
post-transplantation for every pa-
tient included in the analysis.
Target exposure is represented by
the dotted lines. After week 6,
target exposure of ciclosporin A
was minimized from AUC0–24h
10,800 to 6,500 µg*h/L. Week 2
should be regarded as a grouping
variable with the first AUC
measurement as early as 5 days
post-transplantation and a medi-
an of 9 days post-transplantation.
AUC area under the blood con-
centration vs time curve
Eur J Clin Pharmacol (2010) 66:579–590 58730% with a genotype frequency of 20%) would be
clinically relevant early after transplantation. Therefore,
one should consider the dose reduction necessary to reach
the target AUC, in this example within 6 weeks after
transplantation. The median starting dose was 300 mg,
while a median dose decrease of 58% or 125 mg CsA b.i.d.
was necessary to obtain a median AUC decrease of around
2,000 μg*h/L. This demonstrates that relatively large dose
steps are clinically necessary early post-transplantation,
while the genotype effects appear to be small. In addition,
small genotype effects will display overlapping distribu-
tions, harming the specificity of this approach when
applying clinically.
In the literature, only one study was found that was set
up using comparable design and data analysis; in this study,
an age-related effect of ABCB1 polymorphisms on CsA oral
bioavailability was found [33]. This study was performed in
104 pediatric dialysis patients who received a single pre-
transplant intravenous CsA dose and a subgroup also
received an oral dose at least 1 day later. This design has
the advantage that CsA bioavailability could be estimated,
since intravenous and oral data were analyzed simulta-
neously. Both this study and the present study were
comparable with regard to the amount of data analyzed as
well as inclusion of body weight into the model. The
discrepancy with regard to the role of ABCB1 genetic
polymorphisms may be explained by differences in study
populations and co-medication. Fanta et al. [33] analyzed
data from pediatric pre-transplant patients on dialysis who
received a single CsA dose without co-administration of
prednisolone. Specifically, dialysis patients have typical
clinical characteristics such as the presence of a uremic
intestine, which could have a marked effect on absorption
and perhaps on the activity of the intestinal enzymes. Indeed,
adult pre-transplant dialysis patients display highly variable
oral bioavailability [34]. Moreover, co-administration of the
enzyme inducer prednisolone could potentially mask a
relationship between ABCB1 and CsA clearance. Finally,
the population presented in our study is a reflection of a
typical clinical transplantation cohort with patients for whom
therapy with the immunosuppressant CsA is applied. Thus,
from our study we can conclude that the model we presented
including body weight and prednisolone dose, but without
(ABCB1) genotype is adequate for application in an adult
kidney transplant population on triple therapy including
prednisolone, within the first year after transplantation.
The SNPs in the gene encoding the pregnane X receptor
(PXR) were not found to be relevant for explaining
variability in CsA PK. We hypothesize that the nuclear
receptor could be responsible for increased CsA clearance
because of induction of CYP3A4 and ABCB1 [35, 36].
Indeed, prednisolone is able to activate PXR, as described
previously [14], and could in theory be responsible for
increased CsA clearance as observed early after transplan-
tation. Inter-individual variability in this drug–drug inter-
action could potentially be related to polymorphisms in the
gene coding for PXR, as hypothesized previously for
tacrolimus [37]. Yet, the present analysis revealed that all
patients were affected in the same manner by a decrease in
CsA apparent clearance early after transplantation, which
limited the possibility of finding a relationship between
PXR genotype and CsA clearance. Therefore, the covariate
prednisolone dose over 20 mg/day appeared to be sufficient
to explain the decrease in apparent CsA clearance in time.
In addition, the prednisolone dose was rapidly tapered from
100 mg on the day of transplantation to 10 mg once daily in
the first 3 weeks post-transplantation and therefore was
correlated with time post-transplantation. Specifically, in
the first 2 weeks after transplantation a significantly lower
bioavailability was estimated. Furthermore, this could also
be the result of the improved health status of the patients
shortly after transplantation attended with an increase in
CsA binding factors, such as serum albumin concentration
and hematocrit. However, this analysis did not reveal a
covariate effect of these markers. Although unambiguous
evidence for the interaction between prednisolone and CsA
is lacking [38–40], the effect on bioavailability was
attributed to a prednisolone dose in this study and not to
time post-transplantation. Yet, to draw conclusions on this
matter, CsA PK in the absence of prednisolone should be
compared. The effect of prednisolone, or the time post-
transplantation effect, on CsA exposure hinders TDM, as
can be seen from Fig. 3. After the first AUC visit grouped
as week 2, the CsA dose was reduced in the majority of
patients. Interestingly, this dose reduction did not result in a
lower CsA AUC at the next visit. Because the prednisolone
dose was tapered at the same time, CsA clearance decreased
and the AUC remained at the same level. Hence, one
should account for co-administration of prednisolone when
applying a TDM strategy and adjusting the dose.
As described in the Materials and methods section,
steady-state PK was assumed for the analysis of these data.
Three factors could obscure this assumption, namely
dietary fluctuations, variability in dosing intervals, and
compliance issues. Patients were allowed to take a light
breakfast just prior to their TDM visit in the outpatient
clinic. However, most likely the evening before these
patients had taken a heavy meal. This dietary variability
could cause altered CsA concentrations. The same holds
true for daily fluctuations in dosing interval or accidentally
missing a dose. These factors cause fluctuations in PK
parameters over time and were accounted for with intra-
occasion variability.
This population analysis demonstrates that body weight is
an important covariate, while the selected genetic poly-
morphisms appear to have, if any, only a non-clinically
588 Eur J Clin Pharmacol (2010) 66:579–590relevant effect on CsA exposure. In contrast, for tacrolimus
genetic factors were relevant for individualized dosing,
whereas body weight appeared irrelevant [37]. The two
calcineurin inhibitors are often bracketed together because of
their grouping and interchangeable use, which suggest that
they are comparable drugs. However, one should be careful
when comparing these two calcineurin inhibitors as they are
chemically and thus pharmacokinetically very different. Both
display characteristic absorption profiles, since CsA is
mainly absorbed in the upper intestine (duodenum and
proximal jejunum) [41], while tacrolimus is absorbed
throughout a larger part of the intestine (duodenum down
to the ileum) [42]. In addition, these drugs distribute
differently throughout the body and both bind to different
immunophilins, FK-BP and cyclophilin [43]. In blood
both drugs bind to red blood cells, albumin, and α-acid
protein, but in fairly different ways and to different extents
[6, 44, 45]. Finally, they are both metabolized in a unique
pattern [3, 46].
Both CsA and tacrolimus are subject to dose reduction
protocols [1], which inevitably makes variability in expo-
sure an issue for both drugs. CsA displays relatively low
inter-individual variability, at least compared with tacroli-
mus, in which genetic markers have been shown to be
relevant for individualized dosing [18, 37]. In clinical
practice the variability of CsA is handled with TDM. The
unexplained inter-occasion variability (14%) in apparent
clearance is lower than the unexplained inter-individual
variability (17%), which supports the role of TDM. The
low intra-individual variability post-transplantation while
on a stable prednisolone dose indicates that as soon as the
patients’ blood concentrations are adjusted to the target
level, the frequency in monitoring visits could be reduced.
From that moment onward, monitoring is necessary
mostly during conditions, such as infection and diarrhea,
and at times when potentially interactive co-medication is
started.
Conclusion
Individualizing CsA treatment in adult kidney transplant
recipients can be achieved by a body weight-based dosage
followed by a TDM strategy. The CsA dosage should be
adjusted to the decrease in apparent CsA clearance in the
first weeks after transplantation, possibly as a result of
tapering the concomitant prednisolone dose. It appears
that the selected genetic polymorphisms in CYP3A4,
CYP3A5, ABCB1,a n dPXR explain variability in CsA
exposure insufficiently to be of clinical relevance. Geno-
typing for these polymorphisms will probably not lead to
an improved dosing strategy for optimizing exposure early
after transplantation.
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